JP2018513185A - 共結晶組成物及びその医薬用途 - Google Patents
共結晶組成物及びその医薬用途 Download PDFInfo
- Publication number
- JP2018513185A JP2018513185A JP2017555465A JP2017555465A JP2018513185A JP 2018513185 A JP2018513185 A JP 2018513185A JP 2017555465 A JP2017555465 A JP 2017555465A JP 2017555465 A JP2017555465 A JP 2017555465A JP 2018513185 A JP2018513185 A JP 2018513185A
- Authority
- JP
- Japan
- Prior art keywords
- dcp
- pharmaceutical composition
- subject
- disease
- body weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title description 7
- 239000013078 crystal Substances 0.000 title description 5
- IIJQICKYWPGJDT-UHFFFAOYSA-L azane;cyclobutane-1,1-dicarboxylate;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound N.N.[Pt+2].OC(=O)C1(C([O-])=O)CCC1.OC(=O)C1(C([O-])=O)CCC1 IIJQICKYWPGJDT-UHFFFAOYSA-L 0.000 claims abstract description 137
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 70
- 201000010099 disease Diseases 0.000 claims abstract description 69
- 238000000034 method Methods 0.000 claims abstract description 53
- 239000002671 adjuvant Substances 0.000 claims abstract description 25
- 230000002062 proliferating effect Effects 0.000 claims abstract description 16
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 13
- 208000026278 immune system disease Diseases 0.000 claims abstract description 12
- AENCTOAEVOLYHR-UHFFFAOYSA-N azanide cyclobutane-1,1-dicarboxylic acid platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1.OC(=O)C1(C(O)=O)CCC1 AENCTOAEVOLYHR-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 94
- 230000037396 body weight Effects 0.000 claims description 63
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 40
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 38
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 30
- 229940124597 therapeutic agent Drugs 0.000 claims description 23
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 20
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 20
- 229960003180 glutathione Drugs 0.000 claims description 20
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 19
- 201000007094 prostatitis Diseases 0.000 claims description 18
- 239000003937 drug carrier Substances 0.000 claims description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 11
- 229960002949 fluorouracil Drugs 0.000 claims description 11
- 208000024908 graft versus host disease Diseases 0.000 claims description 11
- 241001116389 Aloe Species 0.000 claims description 10
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 10
- 108010024636 Glutathione Proteins 0.000 claims description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 10
- 235000011399 aloe vera Nutrition 0.000 claims description 10
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 10
- 229960001467 bortezomib Drugs 0.000 claims description 10
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 10
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 10
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 10
- 229940109262 curcumin Drugs 0.000 claims description 10
- 235000012754 curcumin Nutrition 0.000 claims description 10
- 239000004148 curcumin Substances 0.000 claims description 10
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 10
- 229960000304 folic acid Drugs 0.000 claims description 10
- 235000019152 folic acid Nutrition 0.000 claims description 10
- 239000011724 folic acid Substances 0.000 claims description 10
- 235000003969 glutathione Nutrition 0.000 claims description 10
- 206010025135 lupus erythematosus Diseases 0.000 claims description 8
- 201000005569 Gout Diseases 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 6
- 208000023328 Basedow disease Diseases 0.000 claims description 5
- 208000015023 Graves' disease Diseases 0.000 claims description 5
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 238000009098 adjuvant therapy Methods 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000007914 intraventricular administration Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 210000003670 sublingual gland Anatomy 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000007919 intrasynovial administration Methods 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 35
- 230000002265 prevention Effects 0.000 abstract description 21
- 210000002307 prostate Anatomy 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 208000009329 Graft vs Host Disease Diseases 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 8
- 229960004562 carboplatin Drugs 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 6
- 229960004316 cisplatin Drugs 0.000 description 6
- 210000004969 inflammatory cell Anatomy 0.000 description 6
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 229930012538 Paclitaxel Natural products 0.000 description 4
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000001934 delay Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- 206010018691 Granuloma Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 208000017497 prostate disease Diseases 0.000 description 3
- 210000002955 secretory cell Anatomy 0.000 description 3
- 230000005808 skin problem Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 description 2
- GJOHLWZHWQUKAU-UHFFFAOYSA-N 5-azaniumylpentan-2-yl-(6-methoxyquinolin-8-yl)azanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 GJOHLWZHWQUKAU-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 2
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 2
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 102000001284 I-kappa-B kinase Human genes 0.000 description 2
- 108060006678 I-kappa-B kinase Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010029155 Nephropathy toxic Diseases 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 2
- 206010068348 X-linked lymphoproliferative syndrome Diseases 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000003430 antimalarial agent Substances 0.000 description 2
- 229940033495 antimalarials Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 2
- 229960004191 artemisinin Drugs 0.000 description 2
- 229930101531 artemisinin Natural products 0.000 description 2
- 229960002970 artemotil Drugs 0.000 description 2
- NLYNIRQVMRLPIQ-XQLAAWPRSA-N artemotil Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OCC)O[C@H]4[C@]32OO[C@@]1(C)O4 NLYNIRQVMRLPIQ-XQLAAWPRSA-N 0.000 description 2
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 description 2
- 229960004991 artesunate Drugs 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960002328 chloroquine phosphate Drugs 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000010370 hearing loss Effects 0.000 description 2
- 231100000888 hearing loss Toxicity 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
- 229960004171 hydroxychloroquine Drugs 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000007694 nephrotoxicity Effects 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- -1 polymorphs Chemical class 0.000 description 2
- 229960005462 primaquine phosphate Drugs 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 2
- 229960000611 pyrimethamine Drugs 0.000 description 2
- 229960000948 quinine Drugs 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010069918 Bacterial prostatitis Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 201000002287 Keratoconus Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010069493 Perennial allergy Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- CCQPAEQGAVNNIA-UHFFFAOYSA-L cyclobutane-1,1-dicarboxylate(2-) Chemical compound [O-]C(=O)C1(C([O-])=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-L 0.000 description 1
- CCQPAEQGAVNNIA-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
DCPは、多数の疾患にかかっている臨床試験患者について徴候を緩和した。中国では、DCP(1〜約10mg/kg体重)は、シスプラチン及びパクリタキセルとの組み合わせで、小細胞肺癌(SCLC)を有する患者のためのフェーズII及びフェーズIII臨床試験において使用された。癌患者は、多数の増殖性疾患、変性疾患、免疫疾患及び上述の他の疾患に同時にかかっていた。例えば、何人かの患者は、関節リウマチ、骨関節症、関節結石(痛風)及び/又は他の疾患にかかっていた。研究者らは、全ての疾患の徴候は、DCP、シスプラチン及びパクリタキセルの組み合わせによって低減されたことを見出した。しかし、かかる組み合わせによって治療された患者は、腎臓毒性、神経毒性、中毒性難聴、吐き気、及び嘔吐のような強い副作用によっても影響を受けた。同じタイプの患者をDCP単独(1〜約10mg/kg体重)で治療すると、DCPは、増殖性疾患、変性疾患、免疫疾患及び上述の他の疾患の徴候を、組み合わせ使用の場合よりずっと効果的に有意に緩和することが明らかになった。かかる疾患は、少なくとも関節リウマチ、骨関節症、関節結石(痛風)を含む。それに加えて、DCPを単独で受け取った患者は、副作用にかかる割合が低く、その副作用も、DCP、シスプラチン及びパクリタキセルの組み合わせと比べて穏やかであった。DCPが、葉酸、補酵素Q10、クルクミン、グルタチオン(GSH)、アロエ、オリザノール、5−フルオロウラシル、及びボルテゾミブなどの追加の治療薬又はアジュバント療法薬と共に投与された場合、疾患の徴候を低減させる効果は、さらに増大された。
ヒト線維芽細胞様滑液分泌細胞関節リウマチ(HFLS−RA)細胞は、インビトロで培養され、細胞の増殖は、処理の48時間後の細胞数を定量することによって測定された。細胞は、1.563μg/ml;3.125μg/ml;6.25μg/ml;12.5μg/ml;25μg/ml;50μg/ml;又は100μg/mlの濃度のDCPで処理された。DCPは、3.914μg/mlのIC50でHFLS−RAの増殖を有意に減少させた。結果は、図1に示されている。
前立腺炎についてのマウスモデルは、DCPの効果を研究するために利用された。DCP組成物での1〜2週間の治療後、非細菌性前立腺炎にかかっていたマウスは、正常に戻った。結果は、図3〜5に示されており、DCPで前立腺炎を治療するためのインビボ病理学的発見を証明する。
癌及び同時に良性前立腺過形成(BPH)にかかっている男性患者(ヒト)におけるDCPの研究では、BPHの徴候は、DCP治療によって有意に緩和された。BPHにかかっていた患者の大多数は、DCPの使用の2週間後に、彼らの前立腺活性が改善した。例えば、前立腺の拡大が明らかに阻害され、PSAが減少し、尿の最大量が12mL/秒以上に増大した。
Claims (20)
- 増殖性疾患、変性疾患、又は免疫疾患の疾患を対象において治療又は予防する方法であって、ジシクロプラチン(DCP)を含む医薬組成物を対象に投与することを含む方法。
- 疾患が、関節リウマチ、痛風、紅斑性狼瘡、骨粗しょう症、乾癬、前立腺炎、良性前立腺過形成(BPH)、多発性硬化症、セリアック病、シェーグレン症候群、橋本甲状腺炎、グレーブス病、及び移植片対宿主病(GVHD)からなる群から選択される、請求項1に記載の方法。
- 疾患が、関節リウマチである、請求項2に記載の方法。
- 疾患が、前立腺炎である、請求項2に記載の方法。
- 疾患が、良性前立腺過形成(BPH)である、請求項2に記載の方法。
- 医薬組成物が、少なくとも一種の治療薬又は少なくとも一種のアジュバント療法薬をさらに含む、請求項1〜5のいずれかに記載の方法。
- 少なくとも一種の治療薬又は少なくとも一種のアジュバント療法薬が、葉酸、補酵素Q10、クルクミン、グルタチオン(GSH)、アロエ、オリザノール、5−フルオロウラシル、及びボルテゾミブからなる群から選択される、請求項6に記載の方法。
- 医薬組成物が、医薬的に許容可能な担体又は賦形剤をさらに含む、請求項1〜7のいずれかに記載の方法。
- 医薬組成物が、口、頬、吸入噴霧、舌下腺、直腸、経皮、膣、経粘膜、局所、鼻、腸、筋肉内、皮下、髄内、髄腔内、脳室内、同所性、皮内、腹腔内、静脈内、関節内、胸骨内、滑液内、肝臓内、病巣内、頭蓋内、腹腔内、鼻腔内、又は眼球内の経路によって投与される、請求項1〜8のいずれかに記載の方法。
- DCPが、対象の免疫学的反応を調節する、請求項1〜8のいずれかに記載の方法。
- 対象に投与される医薬組成物中のDCPの量が、約0.01〜10mg/kg体重の量である、請求項1〜8のいずれかに記載の方法。
- 対象の関節リウマチを治療又は予防する方法であって、有効量のDCPを含む医薬組成物を対象に投与することを含む方法。
- 医薬組成物が、葉酸、補酵素Q10、クルクミン、グルタチオン(GSH)、アロエ、オリザノール、5−フルオロウラシル、及びボルテゾミブからなる群から選択される少なくとも一種の治療薬又は少なくとも一種のアジュバント療法薬をさらに含む、請求項12に記載の方法。
- 有効量のDCPが、約0.01〜5mg/kg体重である、請求項12又は13に記載の方法。
- 対象の前立腺炎を治療又は予防する方法であって、有効量のDCPを含む医薬組成物を対象に投与することを含む方法。
- 医薬組成物が、葉酸、補酵素Q10、クルクミン、グルタチオン(GSH)、アロエ、オリザノール、5−フルオロウラシル、及びボルテゾミブからなる群から選択される少なくとも一種の治療薬又は少なくとも一種のアジュバント療法薬をさらに含む、請求項15に記載の方法。
- 有効量のDCPが、約0.01〜5mg/kg体重である、請求項15又は16に記載の方法。
- 対象のBPHを治療又は予防する方法であって、有効量のDCPを含む医薬組成物を対象に投与することを含む方法。
- 医薬組成物が、葉酸、補酵素Q10、クルクミン、グルタチオン(GSH)、アロエ、オリザノール、5−フルオロウラシル、及びボルテゾミブからなる群から選択される少なくとも一種の治療薬又は少なくとも一種のアジュバント療法薬をさらに含む、請求項18に記載の方法。
- 有効量のDCPが、約0.01〜5mg/kg体重である、請求項18又は19に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562151113P | 2015-04-22 | 2015-04-22 | |
US62/151,113 | 2015-04-22 | ||
PCT/US2016/028720 WO2016172393A1 (en) | 2015-04-22 | 2016-04-21 | Co-crystal composition and its pharmaceutical use |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018513185A true JP2018513185A (ja) | 2018-05-24 |
JP2018513185A5 JP2018513185A5 (ja) | 2019-05-16 |
JP6768702B2 JP6768702B2 (ja) | 2020-10-14 |
Family
ID=57143523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017555465A Active JP6768702B2 (ja) | 2015-04-22 | 2016-04-21 | 共結晶組成物及びその医薬用途 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20180085377A1 (ja) |
EP (1) | EP3285758B1 (ja) |
JP (1) | JP6768702B2 (ja) |
KR (1) | KR102569221B1 (ja) |
CN (2) | CN116602954A (ja) |
AU (1) | AU2016250616B2 (ja) |
BR (1) | BR112017022653A2 (ja) |
CA (1) | CA2983411C (ja) |
WO (1) | WO2016172393A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016265922B2 (en) | 2015-05-18 | 2021-05-20 | Syn-Nat Products Enterprise LLC | A pharmaceutical co-crystal and use thereof |
EP3297636B1 (en) | 2015-06-19 | 2021-02-17 | Syn-Nat Products Enterprise LLC | Pharmaceutical composition of carboplatin based co-crystals and use thereof |
US10980768B2 (en) | 2015-06-19 | 2021-04-20 | Syn-Nat Products Enterprise LLC | Composition containing carboplatin and use |
AU2016284816B2 (en) | 2015-06-25 | 2021-10-07 | Syn-Nat Products Enterprise LLC | Pharmaceutical co-crystal composition and use thereof |
US20200361973A1 (en) * | 2017-11-21 | 2020-11-19 | Medoncare Pharmaceutical Co., Ltd. | Combination product comprising dicycloplatin and preparation method and use thereof |
WO2023093837A1 (zh) * | 2021-11-26 | 2023-06-01 | 湖南湘源美东医药科技有限公司 | 含有铂类药物或者铂类药物共晶的药物组合物及其用途 |
CN116217628B (zh) * | 2023-05-08 | 2023-07-14 | 华东理工常熟研究院有限公司 | 奥沙利铂Pt(IV)配合物的共晶及其制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001238640A (ja) * | 2000-02-28 | 2001-09-04 | Snow Brand Milk Prod Co Ltd | 葉酸及び/又はビタミンb12−ラクトフェリン類複合物 |
JP2002238455A (ja) * | 2001-02-15 | 2002-08-27 | Oriza Yuka Kk | 米油およびその製造方法 |
JP2003529566A (ja) * | 2000-03-03 | 2003-10-07 | シュチン ヤン | 二重ジカルボン酸ジアミノプラチン錯体の抗腫瘍誘導体、その調製方法、それを含む薬剤組成物及びその誘導体の適用方法 |
JP2005506294A (ja) * | 2001-03-06 | 2005-03-03 | ブリストル−マイヤーズ スクイブ カンパニー | テガフル、ウラシル、フォリン酸、パクリタキセルおよびカルボプラチンの投与による腫瘍の治療方法および剤形 |
JP2005510537A (ja) * | 2001-11-29 | 2005-04-21 | サウンド・ファーマシューティカルズ・インコーポレイテッド | 化学療法の所望されない効果を改善する方法および組成物 |
JP2008545965A (ja) * | 2005-05-24 | 2008-12-18 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 癌の治療のための組成物および方法 |
WO2014168993A1 (en) * | 2013-04-08 | 2014-10-16 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
JP2014530878A (ja) * | 2011-10-20 | 2014-11-20 | ネリウム バイオテクノロジー,インコーポレーテッド | 癌治療のための治療用組合せ |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7858331B2 (en) * | 2000-11-03 | 2010-12-28 | Dana Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
CN1681495B (zh) * | 2002-08-19 | 2010-05-12 | 辉瑞产品公司 | 用于治疗过度增生性疾病的组合物 |
-
2016
- 2016-04-21 AU AU2016250616A patent/AU2016250616B2/en active Active
- 2016-04-21 KR KR1020177033399A patent/KR102569221B1/ko active IP Right Grant
- 2016-04-21 CN CN202310609454.8A patent/CN116602954A/zh active Pending
- 2016-04-21 BR BR112017022653A patent/BR112017022653A2/pt not_active IP Right Cessation
- 2016-04-21 JP JP2017555465A patent/JP6768702B2/ja active Active
- 2016-04-21 US US15/567,520 patent/US20180085377A1/en not_active Abandoned
- 2016-04-21 WO PCT/US2016/028720 patent/WO2016172393A1/en unknown
- 2016-04-21 CN CN201680023213.3A patent/CN107530309A/zh active Pending
- 2016-04-21 EP EP16783891.1A patent/EP3285758B1/en active Active
- 2016-04-21 CA CA2983411A patent/CA2983411C/en active Active
-
2022
- 2022-01-31 US US17/588,788 patent/US20220226345A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001238640A (ja) * | 2000-02-28 | 2001-09-04 | Snow Brand Milk Prod Co Ltd | 葉酸及び/又はビタミンb12−ラクトフェリン類複合物 |
JP2003529566A (ja) * | 2000-03-03 | 2003-10-07 | シュチン ヤン | 二重ジカルボン酸ジアミノプラチン錯体の抗腫瘍誘導体、その調製方法、それを含む薬剤組成物及びその誘導体の適用方法 |
JP2002238455A (ja) * | 2001-02-15 | 2002-08-27 | Oriza Yuka Kk | 米油およびその製造方法 |
JP2005506294A (ja) * | 2001-03-06 | 2005-03-03 | ブリストル−マイヤーズ スクイブ カンパニー | テガフル、ウラシル、フォリン酸、パクリタキセルおよびカルボプラチンの投与による腫瘍の治療方法および剤形 |
JP2005510537A (ja) * | 2001-11-29 | 2005-04-21 | サウンド・ファーマシューティカルズ・インコーポレイテッド | 化学療法の所望されない効果を改善する方法および組成物 |
JP2008545965A (ja) * | 2005-05-24 | 2008-12-18 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 癌の治療のための組成物および方法 |
JP2014530878A (ja) * | 2011-10-20 | 2014-11-20 | ネリウム バイオテクノロジー,インコーポレーテッド | 癌治療のための治療用組合せ |
WO2014168993A1 (en) * | 2013-04-08 | 2014-10-16 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
Non-Patent Citations (3)
Title |
---|
ANTICANCER RESEARCH, vol. 34, JPN6020003383, 2014, pages 455 - 463, ISSN: 0004204498 * |
BMC MUSCULOSKELETAL DISORDERS, vol. Vol.14, Suppl.1, JPN6020003381, 2013, pages 5, ISSN: 0004204496 * |
REVISTA DE NEUROLOGIA, vol. 48, no. 2, JPN6020003382, 2009, pages 71 - 74, ISSN: 0004204497 * |
Also Published As
Publication number | Publication date |
---|---|
CA2983411A1 (en) | 2016-10-27 |
US20180085377A1 (en) | 2018-03-29 |
EP3285758A1 (en) | 2018-02-28 |
KR102569221B1 (ko) | 2023-08-21 |
BR112017022653A2 (pt) | 2018-07-10 |
JP6768702B2 (ja) | 2020-10-14 |
CN107530309A (zh) | 2018-01-02 |
KR20170138527A (ko) | 2017-12-15 |
EP3285758A4 (en) | 2018-12-05 |
EP3285758B1 (en) | 2020-04-08 |
CA2983411C (en) | 2023-02-21 |
AU2016250616A1 (en) | 2017-11-09 |
AU2016250616B2 (en) | 2021-01-21 |
WO2016172393A1 (en) | 2016-10-27 |
CN116602954A (zh) | 2023-08-18 |
US20220226345A1 (en) | 2022-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6768702B2 (ja) | 共結晶組成物及びその医薬用途 | |
WO2005117954A3 (en) | Compositions and methods for treatment of neovascular diseases | |
JP5514123B2 (ja) | 卵巣癌を治療するための、パクリタキセルを含む配合剤 | |
Silvestris et al. | Update on capecitabine alone and in combination regimens in colorectal cancer patients | |
JP2004525143A5 (ja) | ||
AU2017384134B2 (en) | Combination of a protein kinase inhibitor and an additional chemotherapeutic agent | |
CA2569739C (en) | Antitumor effect potentiator, antitumor preparation, and method for treating cancer | |
KR20100038061A (ko) | 리마프로스트를 함유하는, 암화학 요법에 기인하는 말초신경장애 예방, 치료 및/또는 증상 경감제 | |
US20190183893A1 (en) | Low dose of sildenafil as an antitumor drug | |
JP5548874B2 (ja) | がん免疫抑制解除剤及びがん免疫治療用組成物 | |
TW201235039A (en) | Composition, kit and use for immune enhancement | |
EP2694056B1 (en) | Therapeutic treatment | |
US20110130374A1 (en) | Small Pyrimidine Derivatives and Methods of Use Thereof | |
TW201235038A (en) | Sensitizer, kit and use for cancer therapy | |
CN102319260A (zh) | 顺铂联合伊曲康唑异构体在制备治疗肺癌药物中的应用 | |
JP2021535163A (ja) | タウロリジン加水分解産物による神経芽細胞腫治療 | |
CN110403924A (zh) | 一种治疗皮肤黑色素瘤的药物组合物及其制备方法 | |
WO2019037671A1 (zh) | 一种治疗癌症的联合用药物 | |
TWI727858B (zh) | 維奈托克(venetoclax)之水溶性高分子衍生物 | |
WO2023093837A1 (zh) | 含有铂类药物或者铂类药物共晶的药物组合物及其用途 | |
JP2007530567A (ja) | エポチロン及びカルボプラチンを用いる併用療法 | |
CN113350370A (zh) | 聚乙二醇在预防和/或治疗肿瘤中的应用 | |
AU2002364165B2 (en) | Process for affecting neurologic progression | |
JP2023500352A (ja) | 移植片対宿主病を予防又は治療するための化合物 | |
KR20230159375A (ko) | 의약에서 사용하기 위한 4-클로로-n-[2-[(4-클로로페닐)메틸]-3-옥소-1,2,4-티아디아졸-5-일]벤즈아미드 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20171023 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190405 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190405 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200131 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200728 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200828 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200923 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6768702 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |